HhAntag

CAS No. 496794-70-8

HhAntag( HhAntag | Hh-Antag | Hh Antag )

Catalog No. M17525 CAS No. 496794-70-8

HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 101 In Stock
5MG 93 In Stock
10MG 170 In Stock
25MG 359 In Stock
50MG 602 In Stock
100MG 918 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    HhAntag
  • Note
    Research use only, not for human use.
  • Brief Description
    HhAntag is a small molecule inhibitor of GLI1-mediated transcription, an essential down-stream element of the Hedgehog (Hh) pathway with the anti-tumor activity.
  • Description
    HhAntag is a GLI1-mediated transcription inhibitor. It acts as an inhibitor of the Shh pathway.
  • In Vitro
    HhAntag (2-30 μM; 72?hours) demonstrates to be?10-times more potent than the natural product SMO antagonist, cyclopamine, at inhibiting Hh pathway activity and it inhibits Hh signalling pathway sensitivitive cells with IC50 values ranging from 2?μM to >30?μM.HhAntag inhibits AsPC-1, BXPC-3, CFPAC, HPAC, HPAF-II, KP4, Panc 03.27, PA-TU-8902, PSN-1, SU.86.86 cells with IC50 values of 30 μM, 5.4 μM, 5.8 μM, 2.7 μM, 6.2 μM,10.3 μM, 2.5 μM, 2.9 μM, 5.8 μM and 2.7 μM, respectively.HhAntag (100 nM) is needed to completely inhibit Hh signalling in a Hh-responsive human mesenchymal cell line (HEPM) expressing a?GLI?luciferase reporter construct (HEPM-rep), the IC50?of 5?nM 400-times lower than that required to inhibit cell growth by 50% in the most sensitive cancer cell line (1.9?μM).
  • In Vivo
    HhAntag (oral administraion; 75 mg/kg or 100 mg/kg; twice daily; 25 days) results in significant growth delay in HT55 and HT-29 colorectal cell line xenografts models, with average tumour growth inhibitions of 29% and 48%, respectively. Whereas HhAntag had no effect on the growth of DLD-1 xenografts. Animal Model:Primary human xenografts?in?female CD1 nu/nu mice of 6–8?weeks (DLD-1, HT55 and HT-29 cells)Dosage:75 mg/kg or 100 mg/kg Administration:Oral administraion; twice daily; 25 days Result:Resulted in growth delay of HT55 and HT-29 xenografts, but had no effects on DLD-1 xenografts.
  • Synonyms
    HhAntag | Hh-Antag | Hh Antag
  • Pathway
    Membrane Transporter/Ion Channel
  • Target
    TRP/TRPV Channel
  • Recptor
    Gli
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    496794-70-8
  • Formula Weight
    450.92
  • Molecular Formula
    C24H23ClN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 100 mg/mL. 221.77 mM; H2O : < 0.1 mg/mL
  • SMILES
    C(=O)(c1cc(cc(c1)OC)OC)Nc1cc(c(cc1)Cl)c1nc2c([nH]1)cc(cc2)N(C)C
  • Chemical Name
    N-[4-Chloro-3-[6-(dimethylamino)-1H-benzimidazol-2-yl]phenyl]-3,5-dimethoxybenzamide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Actis, Marcelo; Connelly, Michele C.; Mayasundari, Anand et al. Biopolymers (2011), 95(1), 24-30.
molnova catalog
related products
  • TRPM4-IN-2

    TRPM4-IN-2 (NBA), also known as NBA, is a highly effective inhibitor of transient receptor potential melastatin 4 (TRPM4).

  • EIPA

    EIPA (L593754, MH 12-43) is a TRPP3 channel inhibitor (IC50: 10.5 μM). It also inhibits Na+/H+-exchanger (NHE) and macropinocytosis.It is found that EIPA, benzamil, and phenamil rapidly and reversibly block Ca2+-activated TRPP3 channel activation at -50 mV, with IC50s of 143, 10.5, 1.1, and 0.14 μM, respectively.

  • PF-04745637

    PF-04745637 is a potent and selective TRPA1 antagonist with an IC50 of 17 nM.